An overview of the role of telomeres and telomerase in pre‑neoplastic lesions (Review)
- Authors:
- Eleftheria Karaviti
- Athanasios Kontogiannis
- Aristotelis Anastopoulos
- Elias Kotteas
- Georgia Gomatou
-
Affiliations: Oncology Unit, Third Department of Medicine, ‘Sotiria’ General Hospital of Diseases of The Chest, National and Kapodistrian University of Athens, Athens 11527, Greece, Oncology Unit, Third Department of Medicine, ‘Sotiria’ General Hospital of Diseases of The Chest, National and Kapodistrian University of Athens, Athens 11527, Greece - Published online on: June 22, 2023 https://doi.org/10.3892/mco.2023.2657
- Article Number: 61
-
Copyright: © Karaviti et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Shay JW and Wright WE: Telomeres and telomerase: Three decades of progress. Nat Rev Genet. 20:299–309. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Roake CM and Artandi SE: Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol. 21:384–397. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, et al: Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 49:349–357. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Maciejowski J and de Lange T: Telomeres in cancer: Tumour suppression and genome instability. Nat Rev Mol Cell Biol. 18:175–186. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cukusić A, Skrobot Vidacek N, Sopta M and Rubelj I: Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res. 122:263–272. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Pestana A, Vinagre J, Sobrinho-Simões M and Soares P: TERT biology and function in cancer: Beyond immortalisation. J Mol Endocrinol. 58:R129–R146. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Colebatch AJ, Dobrovic A and Cooper WA: TERT gene: Its function and dysregulation in cancer. J Clin Pathol. 72:281–284. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L and Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 339:957–959. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, et al: Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 526:700–704. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lewis KA and Tollefsbol TO: Regulation of the telomerase reverse transcriptase subunit through epigenetic mechanisms. Front Genet. 7(83)2016.PubMed/NCBI View Article : Google Scholar | |
|
Dogan F and Forsyth NR: Telomerase regulation: A role for epigenetics. Cancers (Basel). 13(1213)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, et al: DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest. 129:223–229. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Renaud S, Loukinov D, Bosman FT, Lobanenkov V and Benhattar J: CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res. 33:6850–6860. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Li C, Liang Y, Wu M, Xu L and Cai W: Telomerase activity analysis of esophageal carcinoma using microdissection-TRAP assay. Chin Med J (Engl). 115:1405–1408. 2002.PubMed/NCBI | |
|
Yu HP, Xu SQ, Lu WH, Li YY, Li F, Wang XL and Su YH: Telomerase activity and expression of telomerase genes in squamous dysplasia and squamous cell carcinoma of the esophagus. J Surg Oncol. 86:99–104. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Koyanagi K, Ozawa S, Ando N, Mukai M, Kitagawa Y, Ueda M and Kitajima M: Telomerase activity as an indicator of malignant potential in iodine-nonreactive lesions of the esophagus. Cancer. 88:1524–1529. 2000.PubMed/NCBI | |
|
Inai M, Kano M, Shimada Y, Sakurai T, Chiba T and Imamura M: Telomerase activity of the Lugol-stained and -unstained squamous epithelia in the process of oesophageal carcinogenesis. Br J Cancer. 85:1006–1013. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Clément G, Braunschweig R, Pasquier N, Bosman FT and Benhattar J: Methylation of APC, TIMP3, and TERT: A new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol. 208:100–107. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Suzuki K, Kashimura H, Ohkawa J, Itabashi M, Watanabe T, Sawahata T, Nakahara A, Muto H and Tanaka N: Expression of human telomerase catalytic subunit gene in cancerous and precancerous gastric conditions. J Gastroenterol Hepatol. 15:744–751. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Wang Z, Xu J, Geng X and Zhang W: Analysis of DNA methylation status of the promoter of human telomerase reverse transcriptase in gastric carcinogenesis. Arch Med Res. 41:1–6. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Duarte MC, Babeto E, Leite KR, Miyazaki K, Borim AA, Rahal P and Silva AE: Expression of TERT in precancerous gastric lesions compared to gastric cancer. Braz J Med Biol Res. 44:100–104. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Silva TC, Leal MF, Calcagno DQ, de Souza CR, Khayat AS, dos Santos NP, Montenegro RC, Rabenhorst SH, Nascimento MQ, Assumpção PP, et al: hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions. BMC Gastroenterol. 12(85)2012.PubMed/NCBI View Article : Google Scholar | |
|
Hu H, Zhang Y, Zou M, Yang S and Liang XQ: Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. J Cancer Res Clin Oncol. 136:1407–1414. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kanamaru T, Tanaka K, Kotani J, Ueno K, Yamamoto M, Idei Y, Hisatomi H and Takeyama Y: Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer. Int J Mol Med. 10:205–210. 2002.PubMed/NCBI | |
|
Choi JY, Yoon H, Na G, Choi YJ, Shin CM, Park YS, Kim N and Lee DH: Evaluation of the expression of the inhibitor of apoptosis protein family and human telomerase reverse transcriptase in patients with advanced colorectal adenoma. J Cancer Prev. 22:98–102. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Saleh S, Lam AK and Ho YH: Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer. Pathology. 40:25–30. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Riegert-Johnson DL, Boardman LA, Crook JE, Thomas CS, Johnson RA and Roberts ME: Shorter peripheral blood telomeres are a potential biomarker for patients with advanced colorectal adenomas. Int J Biol Markers. 27:e375–e380. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Roger L, Jones RE, Heppel NH, Williams GT, Sampson JR and Baird DM: Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst. 105:1202–1211. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Hardikar S, Burnett-Hartman AN, Phipps AI, Upton MP, Zhu LC and Newcomb PA: Telomere length differences between colorectal polyp subtypes: A colonoscopy-based case-control study. BMC Cancer. 18(513)2018.PubMed/NCBI View Article : Google Scholar | |
|
Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M and Zucman-Rossi J: Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 60:1983–1992. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and Zucman-Rossi J: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 4(2218)2013.PubMed/NCBI View Article : Google Scholar | |
|
Matsuda Y, Ishiwata T, Izumiyama-Shimomura N, Hamayasu H, Fujiwara M, Tomita K, Hiraishi N, Nakamura K, Ishikawa N, Aida J, et al: Gradual telomere shortening and increasing chromosomal instability among PanIN grades and normal ductal epithelia with and without cancer in the pancreas. PLoS One. 10(e0117575)2015.PubMed/NCBI View Article : Google Scholar | |
|
Shimonishi T, Sasaki M and Nakanuma Y: Precancerous lesions of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 7:542–550. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Hansel DE, Meeker AK, Hicks J, De Marzo AM, Lillemoe KD, Schulick R, Hruban RH, Maitra A and Argani P: Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma. Mod Pathol. 19:772–779. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Aoki Y, Aida J, Kawano Y, Nakamura KI, Izumiyama-Shimomura N, Ishikawa N, Arai T, Nakamura Y, Taniai N, Uchida E, et al: Telomere length of gallbladder epithelium is shortened in patients with congenital biliary dilatation: Measurement by quantitative fluorescence in situ hybridization. J Gastroenterol. 53:291–301. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ichikawa Y, Kamiyama M, Sekido H, Ishikawa T, Miura Y, Kamiya N, Morita T and Shimada H: Telomerase activity and Bcl-2 expression in gallbladders of pancreaticobiliary maljunction patients: A preliminary study. J Hepatobiliary Pancreat Surg. 11:34–39. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Ishizumi T, McWilliams A, MacAulay C, Gazdar A and Lam S: Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev. 29:5–14. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Greenberg AK, Yee H and Rom WN: Preneoplastic lesions of the lung. Respir Res. 3(20)2002.PubMed/NCBI View Article : Google Scholar | |
|
Lantuejoul S, Soria JC, Morat L, Lorimier P, Moro-Sibilot D, Sabatier L, Brambilla C and Brambilla E: Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res. 11:2074–2082. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C and Brambilla E: Telomere maintenance and DNA damage responses during lung carcinogenesis. Clin Cancer Res. 16:2979–2988. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kang JU, Koo SH, Kwon KC, Park JW and Kim JM: Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet. 182:1–11. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Raynaud CM, Hernandez J, Llorca FP, Nuciforo P, Mathieu MC, Commo F, Delaloge S, Sabatier L, André F and Soria JC: DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 33:341–345. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN and Griffith JK: Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Res Treat. 117:17–24. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Simícková M, Nekulová M, Pecen L, Cernoch M, Vagundová M and Pacovský Z: Quantitative determination of telomerase activity in breast cancer and benign breast diseases. Neoplasma. 48:267–273. 2001.PubMed/NCBI | |
|
Nagai N, Oshita T, Murakami J and Ohama K: Semiquantitative analysis of telomerase activity in cervical cancer and precancerous lesions. Oncol Rep. 6:325–328. 1999.PubMed/NCBI | |
|
Liu Y, Fan P, Yang Y, Xu C, Huang Y, Li D, Qing Q, Sun C and Zhou H: Human papillomavirus and human telomerase RNA component gene in cervical cancer progression. Sci Rep. 9(15926)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhu Y, Han Y, Tian T, Su P, Jin G, Chen J and Cao Y: MiR-21-5p, miR-34a, and human telomerase RNA component as surrogate markers for cervical cancer progression. Pathol Res Pract. 214:374–379. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ravaioli S, Tumedei MM, Amadori A, Puccetti M, Chiadini E and Bravaccini S: Role of telomerase in cervical lesions as prognostic marker: A comparison between immunohistochemistry and fluorescence in situ hybridization. J Low Genit Tract Dis. 21:42–46. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhao XY, Cui Y, Jiang SF, Liu KJ, Han HQ, Liu XS and Li Y: Human telomerase gene and high-risk human papillomavirus infection are related to cervical intraepithelial neoplasia. Asian Pac J Cancer Prev. 16:693–697. 2015.PubMed/NCBI View Article : Google Scholar | |
|
He H, Pan Q, Pan J, Chen Y and Cao L: Study on the correlation between hTREC and HPV load and cervical CINI/II/III lesions and cervical cancer. J Clin Lab Anal. 34(e23257)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang SZ, Sun JH, Zhang W, Jin SQ, Wang HP, Jin YS, Qu P, Liu Y and Li M: Telomerase activity in cervical intraepithelial neoplasia. Chin Med J (Engl). 117:202–206. 2004.PubMed/NCBI | |
|
Van Doorslaer K and Burk RD: Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology. 433:216–219. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ji W, Lou W, Hong Z, Qiu L and Di W: Genomic amplification of HPV, h-TERC and c-MYC in liquid-based cytological specimens for screening of cervical intraepithelial neoplasia and cancer. Oncol Lett. 17:2099–2106. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Alnafakh RAA, Adishesh M, Button L, Saretzki G and Hapangama DK: Telomerase and telomeres in endometrial cancer. Front Oncol. 9(344)2019.PubMed/NCBI View Article : Google Scholar | |
|
Kyo S, Kanaya T, Takakura M, Tanaka M and Inoue M: Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer. 80:60–63. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Maida Y, Kyo S, Forsyth NR, Takakura M, Sakaguchi J, Mizumoto Y, Hashimoto M, Nakamura M, Nakao S and Inoue M: Distinct telomere length regulation in premalignant cervical and endometrial lesions: Implications for the roles of telomeres in uterine carcinogenesis. J Pathol. 210:214–223. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Danescu A, Herrero Gonzalez S, Di Cristofano A, Mai S and Hombach-Klonisch S: Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development. Genes Chromosomes Cancer. 52:716–732. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Datar RH, Naritoku WY, Li P, Tsao-Wei D, Groshen S, Taylor CR and Imam SA: Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas. Gynecol Oncol. 74:338–345. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Sun PM, Wei LH, Luo MY, Liu G, Wang JL, Mustea A, Könsgen D, Lichtenegger W and Sehouli J: The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 130:249–257. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, et al: TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol. 31:1107–1115. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Gunes C, Wezel F, Southgate J and Bolenz C: Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nat Rev Urol. 15:386–393. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cheng L, Montironi R and Lopez-Beltran A: TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential. Eur Urol. 71:497–498. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cheng L, Davidson DD, Wang M, Lopez-Beltran A, Montironi R, Wang L, Tan PH, MacLennan GT, Williamson SR and Zhang S: Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology. 69:107–113. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Isharwal S, Hu W, Sarungbam J, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Jadallah S, Loo FL, et al: Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol. 248:260–265. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Rodriguez Pena MDC, Tregnago AC, Eich ML, Springer S, Wang Y, Taheri D, Ertoy D, Fujita K, Bezerra SM, Cunha IW, et al: Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch. 471:761–767. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Taylor AS, Newell B, Chinnaiyan AM, Hafez KS, Weizer AZ, Spratt DE, Cameron AP, Al-Ahmadie HA, Gupta S, Montgomery JS, et al: TERT promoter mutations in keratinizing and nonkeratinizing squamous metaplasia of the urinary tract. Eur Urol Open Sci. 35:74–78. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, Tögel L, Geppert CI, Sikic D, Taubert H, Wach S, et al: TERT promoter mutation analysis of whole-organ mapping bladder cancers. Genes. 12(230)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tu L, Huda N, Grimes BR, Slee RB, Bates AM, Cheng L and Gilley D: Widespread telomere instability in prostatic lesions. Mol Carcinog. 55:842–852. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Graham MK and Meeker A: Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol. 14:607–619. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cheng L, Montironi R, Davidson DD, Wang M, Lopez-Beltran A and Zhang S: Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. Mol Carcinog. 58:1272–1278. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Rybicki BA, Sadasivan SM, Chen Y, Loveless I, Gupta NS, Chitale DA, Williamson SR, Rundle AG and Tang DL: Race differences in telomere length in benign prostate biopsies and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 31:991–998. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Patel B, Taiwo R, Kim AH and Dunn GP: TERT, a promoter of CNS malignancies. Neurooncol Adv. 2(vdaa025)2020.PubMed/NCBI View Article : Google Scholar | |
|
Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, Jenkins RB and Wrensch MR: Telomere maintenance and the etiology of adult glioma. Neuro Oncol. 17:1445–1452. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Srinivas N, Neittaanmäki N, Heidenreich B, Rachakonda S, Karppinen TT, Grönroos M, Tani TT, Salmivuori M, Snellman E, Hemminki K and Kumar R: TERT promoter mutations in actinic keratosis before and after treatment. Int J Cancer. 146:2932–2934. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ventura A, Pellegrini C, Cardelli L, Rocco T, Ciciarelli V, Peris K and Fargnoli MC: Telomeres and telomerase in cutaneous squamous cell carcinoma. Int J Mol Sci. 20(1333)2019.PubMed/NCBI View Article : Google Scholar | |
|
Fullen DR, Zhu W, Thomas D and Su LD: hTERT expression in melanocytic lesions: An immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol. 32:680–684. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M and Luzi P: Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum Pathol. 31:1018–1021. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter mutations in familial and sporadic melanoma. Science. 339:959–961. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, et al: The genetic evolution of melanoma from precursor lesions. N Engl J Med. 373:1926–1936. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Taylor RS, Ramirez RD, Ogoshi M, Chaffins M, Piatyszek MA and Shay JW: Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol. 106:759–765. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Chang KP, Wang CI, Pickering CR, Huang Y, Tsai CN, Tsang NM, Kao HK, Cheng MH and Myers JN: Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head Neck. 39:1131–1137. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Raghunandan BN, Sanjai K, Kumaraswamy J, Papaiah L, Pandey B and Jyothi BM: Expression of human telomerase reverse transcriptase protein in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical study. J Oral Maxillofac Pathol. 20:96–101. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Aida J, Kobayashi T, Saku T, Yamaguchi M, Shimomura N, Nakamura K, Ishikawa N, Maruyama S, Cheng J, Poon SS, et al: Short telomeres in an oral precancerous lesion: Q-FISH analysis of leukoplakia. J Oral Pathol Med. 41:372–378. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Raju KL, Haragannavar VC, Patil S, Rao RS, Nagaraj T, Augustine D, Venkatesiah SS and Nambiar S: Expression of hTERT in oral submucous fibrosis and oral squamous cell carcinoma-an immunohistochemical analysis. Pathol Oncol Res. 26:1573–1582. 2020.PubMed/NCBI View Article : Google Scholar | |
|
George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY and Clayman GL: Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J Clin Endocrinol Metab. 100:E1550–E1559. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA and Fagin JA: Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 98:E1562–E1566. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu R and Xing M: Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer. 21:825–830. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C and Xu D: The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 33:4978–4984. 2014.PubMed/NCBI View Article : Google Scholar | |
|
McKelvey BA, Umbricht CB and Zeiger MA: Telomerase reverse transcriptase (TERT) regulation in thyroid cancer: A Review. Front Endocrinol (Lausanne). 11(485)2020.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 99:E1130–E1136. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP, et al: Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 120:3627–3634. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M and Alzahrani AS: TERT promoter mutations in thyroid cancer: A report from a Middle Eastern population. Endocr Relat Cancer. 22:901–908. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Su JJ, Hui LZ, Xi CJ and Su GQ: Correlation analysis of ultrasonic characteristics, pathological type, and molecular markers of thyroid nodules. Genet Mol Res. 14:9–20. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Suh YJ, Kwon MJ, Noh HM, Lee HK, Ra YJ and Kim NY: Limited clinical and diagnostic utility of circulating tumor DNA detection in patients with early-stage well-differentiated thyroid cancer: Comparison with benign thyroid nodules and healthy individuals. Healthcare (Basel). 9(386)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kachko VA, Vanushko VE, Platonova NM, Abrosimov AY and Mel'nichenko GA: Somatic mutations in the BRAF, KRAS, NRAS, EIF1AX, and TERT genes: Diagnostic value in thyroid neoplasms. Bull Exp Biol Med. 169:669–672. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al: Frequency of TERT promoter mutations in human cancers. Nat Commun. 4(2185)2013.PubMed/NCBI View Article : Google Scholar | |
|
Topf MC, Wang ZX, Tuluc M and Pribitkin EA: TERT, HRAS, and EIF1AX mutations in a patient with follicular adenoma. Thyroid. 28:815–817. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Höög A, Larsson C and Xu D: TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 120:2965–2979. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Boaventura P, Batista R, Pestana A, Reis M, Mendes A, Eloy C, Sobrinho-Simões M and Soares P: TERT promoter mutations: A genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation. Eur J Endocrinol. 176:49–55. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sayiner A and Suren D: Expression of human telomerase reverse transcriptase (hTERT) in thyroid neoplasms. J BUON. 23:229–233. 2018.PubMed/NCBI | |
|
Pestana A, Batista R, Celestino R, Canberk S, Sobrinho-Simões M and Soares P: Comprehensive assessment of TERT mRNA expression across a large cohort of benign and malignant thyroid tumours. Cancers (Basel). 12(1846)2020.PubMed/NCBI View Article : Google Scholar | |
|
Paulsson JO, Mu N, Shabo I, Wang N, Zedenius J, Larsson C and Juhlin CC: TERT aberrancies: A screening tool for malignancy in follicular thyroid tumours. Endocr Relat Cancer. 25:723–733. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Seow WJ, Cawthon RM, Purdue MP, Hu W, Gao YT, Huang WY, Weinstein SJ, Ji BT, Virtamo J, Hosgood HD III, et al: Telomere length in white blood cell DNA and lung cancer: A pooled analysis of three prospective cohorts. Cancer Res. 74:4090–4098. 2014.PubMed/NCBI View Article : Google Scholar | |
|
McNally EJ, Luncsford PJ and Armanios M: Long telomeres and cancer risk: The price of cellular immortality. J Clin Invest. 129:3474–3481. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Gomatou G, Masaoutis C, Vamvakaris I, Kotteas E, Bouros E, Tzilas V and Bouros D: Differential immunohistochemical expression of hTERT in lung cancer patients with and without idiopathic pulmonary fibrosis. Pulmonology: S2531-0437(22)00002-2, 2022 (Epub ahead of print). | |
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, Voegele C, Poustchi H, Khoshnia M, Roshandel G, et al: Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan cohort study. EBioMedicine. 53(102643)2020.PubMed/NCBI View Article : Google Scholar |
